GRI Bio Inc. Common Stock (NASDAQ: GRI)
$1.78
+0.0600 ( +3.49% ) 5.8K
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Market Data
Open
$1.78
Previous close
$1.72
Volume
5.8K
Market cap
$1.04M
Day range
$1.75 - $1.77
52 week range
$1.46 - $370.37
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 17 | Jul 08, 2024 |
8-k | 8K-related | 20 | Jun 27, 2024 |
8-k | 8K-related | 16 | Jun 18, 2024 |
8-k | 8K-related | 19 | Jun 14, 2024 |
8-k | 8K-related | 15 | Jun 07, 2024 |
8-k | 8K-related | 15 | May 22, 2024 |
8-k | 8K-related | 18 | May 20, 2024 |
8-k | 8K-related | 43 | May 13, 2024 |
10-q | Quarterly Reports | 65 | May 10, 2024 |
def | Proxies and info statements | 4 | May 09, 2024 |